Objective: Evaluate the effect of radiosynovectomy of the ankle with samarium-153 and yttrium-90 in hemophilic arthropathy through the possible reduction of hemarthrosis, analyzing complications, adverse effects, and the need for complementary therapies. Methods: Radiosynovectomy of the ankle in 15 hemophilic patients was analyzed retrospectively and followed between January 2008 and December 2021. The analysis was performed through patients’ medical records and diaries to quantify hemarthrosis that occurred six months before and six months after the procedure. Clinical follow-up and evaluation of outcomes were also analyzed. Results: Eighteen radiosynovectomies of the ankle were performed in 15 patients with a mean follow-up of 124 months. A reduction in episodes of haemarthrosis has been demonstrated within six months (p<0.001). There were no adverse effects or complications in the short and long term. Approximately 61.1% of the patients did not require complementary therapies afterward. Conclusion: The study demonstrated that radiosynovectomy of the ankle with samarium-153 and yttrium-90 in hemophilic patients is effective and safe. There was a decreased frequency of hemarthrosis, less need for complementary procedures, and no complications and adverse effects. Level of Evidence IV, Case Series.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.